Body Protection Compound 157 · 15 mg / vial- ·3 mL bacteriostatic water
- ·10 × 1 mL insulin syringes
- ·Alcohol swabs
BPC-157 15 mg
Pentadecapeptide — 15-residue fragment of a gastric body-protection protein.
15-residue synthetic pentadecapeptide. Most extensively studied in rodent tendon, ligament, skin, and gastric-mucosal models.
What the peptide is.
BPC-157 (Body Protection Compound 157) is a 15-residue synthetic peptide, first described in the 1990s as a fragment of a larger gastric-juice protein. Reported as stable in human gastric juice over extended periods.
The preclinical literature — mostly from the Sikirić group at the University of Zagreb — covers tendon, ligament, gut-mucosal, and vascular indications. Human clinical trials are absent.
Proposed: modulation of nitric-oxide synthesis, VEGFR-2 signalling, FAK–paxillin cytoskeletal pathways. Specific molecular target not conclusively identified.
Reconstitution, storage, and handling.
Lab-technical guidance for the researcher handling the material. Not therapeutic dosing, not administration guidance — those are not within the scope of this supply.
- Recommended solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- Inject diluent slowly down the side of the vial onto the cake.
- Swirl gently — do not shake.
- Solution should be clear and colourless. Discard if not.
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life · sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
- Shelf life · reconstituted
- Up to 4 weeks refrigerated.
- ▸Readily soluble; gentle swirl, no vigorous agitation needed.
This lot, documented.
Every shipment is accompanied by a signed four-page analytical report including the HPLC chromatogram, ESI-MS spectrum, purity calculation, and sample handling chain-of-custody.
The report you will receive is specific to the lot dispatched to you. The display below is a current representative example.
04:22:11▸lot 26-04-A received ┈ 5.00 g04:22:40▸weight check ┈ PASS ±0.4 mg04:23:12▸sample → janoshik ┈ 50 mg04:23:12▸tracking #jnk-921833405:18:03▸HPLC result ┈ 99.24 %05:18:04▸MS obs 4729.42 Da ┈ PASS05:18:05▸coa.pdf signed ┈ attached05:18:06▸lot approved ┈ LIVE
REPORT ID JA-26-04-012
SUBJECT BPC-157 15 mg
DESIGNATION Body Protection Compound 157
LOT 26-04-A
METHOD RP-HPLC, ESI-MS
COLUMN C18, 250 x 4.6 mm, 5 um
MOBILE PHASE A: 0.1% TFA in H2O
B: 0.1% TFA in ACN
GRADIENT 5 -> 65% B over 20 min
FLOW RATE 1.0 mL/min
DETECTION UV 214 nm
INJECTION 20 uL @ 0.5 mg/mL
---
PURITY (A%) 99.40
MASS EXP. 1419.55 Da
MASS OBS. 1419.57 Da
---
CONCLUSION Identity CONFIRMED · Purity PASS
SIGNED BY J. Novak, MSc · Janoshik Analytical SVK
DATE 2026-04-11Research references for BPC-157 15 mg.
3 peer-reviewed publications. Links resolve to PubMed. DOIs are provided where available.
- [01]Sikirić P, et al.
Toxicity by NSAIDs: counteraction by stable gastric pentadecapeptide BPC 157
Current Pharmaceutical Design · 2013 - [02]Chang CH, et al.
BPC 157 on tendon healing
Journal of Applied Physiology · 2011 - [03]Seiwerth S, et al.
Stable gastric pentadecapeptide BPC 157 and wound healing
Frontiers in Pharmacology · 2021
- Q.Why no human clinical data?
- A.No Phase 2/3 human trials have been completed. The evidence base is predominantly rodent models. Omega Grade describes it honestly — extensive preclinical literature, minimal clinical data.
This peptide is supplied by Omega Grade for in vitro laboratory research use. It is not a drug, food, cosmetic, or dietary supplement. It is not approved by the FDA, EMA, MHRA, PMDA, or any other regulatory authority for any therapeutic indication.
No claim of therapeutic benefit is made or implied. The material is not intended for human or veterinary consumption, administration, or any form of self-experimentation. By purchasing, you acknowledge the researcher terms and accept full responsibility for local import compliance and all handling.
Often considered alongside.
BPC-157 + TB-500 10/10 mg kit
Paired regenerative peptides — combined kit, most-requested blend.
- Form
- Lyophilised kit
- Dose
- 10 mg BPC-157 + 10 mg TB-500 / vial
- Purity
- ≥ 99.0% (both peptides)
BPC-157 oral (60 × 500 mcg tablets)
Oral / sublingual tablet presentation — 60 tablets × 500 mcg.
- Form
- Oral tablets
- Dose
- 500 mcg / tablet (60-tablet supply)
- Purity
- ≥ 99.4% active
TB-500 10 mg
Synthetic thymosin β-4 — 43-residue actin-sequestering peptide.
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 99.1%